ABSTRACT
The COVID-19 pandemic highlighted the need for effective protection and rapid development of tests to track and quantify seroconversion through natural infection and vaccination. Recombinant proteins, consisting of the SARS-CoV-2 nucleocapsid and Spike Receptor Binding Domains (RBD) fused with nanoluciferase reporters (GloBodies) were designed and produced. The SARS-CoV-2 specific antibody within serum, from venous blood or eluted from local or remotely-obtained dried blood spots, form a complex with the GloBody, which can be captured on immobilized Protein G or anti-isotype antibody with the retained nanoluciferase activity being proportional to specific antibody levels. Natural infection, vaccination and human and animal SARS-CoV-2 specific antibodies were detectable. These were used to serially monitor infection and vaccination responses in dental healthcare workers (n=82), medical healthcare workers (n=72) and laboratory-based scientists (n=62) within the Royal London, dental and medical hospitals and associated university research institute in Whitechapel, East London. This indicated temporally distinct infection and vaccination profiles, consistent with hospital deployments and local and national lockdowns by dentists and scientists. As such, medical healthcare workers had twice the odds of experiencing COVID-19 symptoms (2.01 95%CI 1.13- 3.58. P<0.001) compared to dentists, who were more at risk than scientists. Likewise, those who performed virus exposure-prone procedures exhibited twice (1.98. 95% CI 1.18-3.34 P=0.01) the odds of symptoms and exhibited higher nucleocapsid titres (0.21 95%CI 0.05-0.38. P=0.012), indicative of higher infection levels. As predicted vaccination was associated with reduced infection risk as shown by reduced titre of nucleocapsid titres (-0.21 95% CI -0.34- - 0.17. P<0.001 and elevated Log10 RBD GloBody titres (1.18. 95%CI 1.09-1.26. P<0.001). The GloBody technology proved to be a versatile and scalable platform for rapid deployment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Medical College of Saint Bartholomews Hospital Trust awarded a grant to ASK to initiate assay development with additional support from the multiple sclerosis community via crowdfunding by GG and ASK. PLR was awarded a grant from The Faculty of Dental Surgery (Royal College of Surgeons of England) to monitor HCW within the Dental Hospital. ANA received a Peter Enzor/Sir John Zochonis intercalated bursary from Worshipful Company of Tallow Chandlers. ANA, ORM, MRJ, and CHYC also received a Rod Flowers Vacation Scholarship. ASK received an award from the National Institute of Health Research: Rapid, Sensitive Detection of Resistance to Therapeutic Antibodies. Product Development NIHR201645
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with applicable guidelines of Good Clinical Practice under UK Clinical Trial Regulations (SI2004, 1031, as amended). Written informed consent was obtained from each participant following Ethical Approval under Integrated Research Application System numbers IRAS 285071 and IRAS 284940 and Research Ethics Committee numbers 20/HRA/2743 and 20/NE/0176. Additional pre-vaccination, diagnostically-tested samples were obtained with ethical approval 20/HRA/2675, ISRCTN15634328 and blindly analysed.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint senior authors
The author Upkar S Gill was missing from the webpage that you published. It seems it not save in the author list but was on the pdf document published. I remeber doing this because Upkar was one of the few people with an existing MedRXiv profile. This has been added and so I trust this will be visible on the webpage. The middle initial of Ryan, Holden and Jones (Rhiannon) have been added in the author list
Data Availability
Anonymized study data may be requested by qualified researchers from SG (s.gnanapavan{at}nhs.net). Requests for unique reagents and methodology should be directed to ASK (a.s.kang{at}qmul.ac.uk).
